KEY DETAILS
An October 27, 2026 meta-analysis of randomized trials found no clear evidence that GLP-1 drugs' relative heart effects differed by age.
An unreviewed October 28 preprint found first-time obesity prescribing of tirzepatide up 10.1% and semaglutide down 12.5% since June.
An October 28, 2026 phase 2 trial linked acmopatide to better glucose control and weight loss in type 1 diabetes with overweight or obesity.
As of October 28, 2026, McMaster's phase 4 trial comparing tirzepatide and semaglutide on energy balance in adults with obesity is recruiting.
Mississippi HB 1136, on telemedicine prescribing of obesity drugs, died on calendar with a last action on February 12, 2026.
A meta-analysis published on October 27, 2026 in Diabetes, Obesity and Metabolism found that GLP-1 receptor agonists lowered major adverse cardiovascular events in the age groups it examined. It found no clear evidence that the relative heart effects of these drugs differed by age. This may be helpful context if you have wondered whether trial results apply to people younger or older than you. The rest of this roundup covers new research records and one older state bill.
Here is the finding in a little more detail. The study, available through its DOI at https://doi.org/10.1111/dom.71496, is described as an updated meta-analysis of randomized controlled trials. Across the included trial populations, GLP-1 receptor agonists lowered major adverse cardiovascular events in the age groups examined. The exact wording is careful, and it helps to keep it that way. The authors reported no clear evidence that the relative cardiovascular effects differed by age.
This one comes with an important caveat. The report is a medRxiv preprint dated October 28, 2026, and it has not been peer reviewed. From June to September, first-time tirzepatide prescribing for obesity rose by 10.1%, while first-time semaglutide prescribing for obesity fell by 12.5%. There is one more number in the report. First-time prescribing for obesity as a whole rose from June to July before declining, and the September rate was relatively stable compared with June, at 3.7% higher.
This one is worth reading closely. The study was a phase 2, double-blind, randomized, placebo-controlled trial in adults with type 1 diabetes and overweight or obesity, published in Diabetes Care on October 28, 2026. The record describes acmopatide, also called CT-868, as a fully biased GLP-1/GIP receptor agonist. The authors reported that acmopatide was associated with improved glycemic control and clinically meaningful weight loss without diabetic ketoacidosis (DKA) or severe hypoglycemia events.
Here is what the record lays out. McMaster University is sponsoring this phase 4 trial, which aims to learn whether 12 weeks of tirzepatide and semaglutide differ in their effect on energy balance in adults with obesity and without known diabetes. Participants will take either tirzepatide or semaglutide once weekly for 12 weeks, and the planned enrollment is 80 people. Because the trial is still recruiting, it has no results yet.
Here is where this one stands. Mississippi HB 1136, from the 2026 session, is titled "Obesity medicine; define as within practice of medicine and allow physicians to prescribe obesity drugs via telemedicine." Its status reads Died On Calendar, and its last action was on February 12, 2026. The record lists one sponsor.
There is more in the full records than fits here. Each item tracked on October 29, 2026, including the other preprints and trials, links to its full record on glp1laws.com. You can read each one in full there.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.